
    
      Enrolment of 16 subjects is planned. Each subject will take part in 2 study periods.

      In Period 1, subjects will receive a single oral dose of 2 mg midazolam on Day 1 and a single
      oral dose of 40 mg atorvastatin on Day 3.

      In Period 2, subjects will receive twice-daily oral doses of 300 mg aramchol (the IMP) for 18
      days. During aramchol dosing, subjects will take a single dose of 2 mg midazolam in the
      morning on Day 10 and 40 mg atorvastatin in the morning on Day 12.

      Subjects will be screened within 21 days before their first dose of study medicine. In Period
      1, they will remain resident on the ward from Day -1 to Day 10. In Period 2, subjects will be
      admitted on Day -1 and discharged on Day 19. Subjects will attend a follow-up visit
      approximately 2 weeks later, on Day 33 (Â±2 days). There will be an interval of at least 1 day
      between Periods 1 and 2.
    
  